huge hepatocellular carcinoma
Conditions
Interventions
Transcatheter arterial chemoembolization (TACE) plus Sorafenib Group:ranscatheter arterial chemoembolization (TACE) plus Sorafenib
Sponsors
Shanghai Eastern Hepatobiliary Hospital
Eligibility
Sex/Gender
Male
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. voluntarily participates in the group with good compliance; cooperates with experimental observation and signs a written informed consent form; 2. with KPS score of the general condition >=60; 3. Aged 18 to 70 years; 4. no history of other malignant tumors; 5. no history of preoperative anti-tumor therapy; 6. WBC count > 3000/L; absolute neutrophil count > 1500/L; platelet count > 50000/L; creatinine 45%; 7. liver function of Child-Pugh class A, without cirrhosis or with mild cirrhosis, without ascites, without hepatic encephalopathy; 8. without gross tumor thrombus of portal/hepatic vein; 9. without distant metastasis; 10. adequate predicted postoperative liver volume; 11. without contraindications for surgery, TACE and sorafenib.
Exclusion criteria
Exclusion criteria: 1. pregnant and lactating women; 2. subjects with poor general condition and obvious impairment of liver function (bilirubin > 3 times the upper limit of normal value, serum albumin < 30g/L); 3. subjects with severe heart, kidney and blood diseases; 4. subjects with poor compliance; 5. subjects who have a history of allergy to chemotherapy drugs, allergic constitution or are in an allergic state; 6. subjects with treatment-related contraindications; 7. subjects with predicted survival of < 5 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall Survival;Overall Survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| progression-free survival; | — |
Countries
China
Contacts
Public ContactXia Yong
Shanghai Eastern Hepatobiliary Hospital
Outcome results
None listed